Navigation Links
Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology

B: BVTI), is currently in a Fast-Tracked Phase 3 clinical trial. The Company is also proposing to enter Phase 3 clinical trials for Multiple Sclerosis using Revimmune(TM), which uses an approved drug in an exclusively licensed method of therapy to "reboot" a patient's immune system. Revimmune was developed at the Johns Hopkins School of Medicine for the elimination of autoimmunity, and Accentia has acquired the exclusive worldwide rights for all autoimmune diseases. For further information, please visit www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about SinuNase, BiovaxID, AutovaxID, Revimmune and any other statements relating to products, product candidates, product development programs the FDA or clinical trial process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange C
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
7. VIVUS Announces Abstract Published at American Diabetes Association Scientific Sessions
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
11. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
Post Your Comments:
(Date:6/18/2013)... PROSPECT, Ill. , June 18, 2013 /PRNewswire-iReach/ ... of its new X3130 Appliance Inlet Module. The ... circuit breaker , combines a C14 appliance inlet ... one compact package.  This three-in-one device allows design ... their designs - cutting installation time by 66 ...
(Date:6/18/2013)... PARSIPPANY, N.J. , June 18, 2013  Actavis, Inc. ... ("New Actavis") has filed with the U.S. Securities and Exchange ... with Actavis, proposed acquisition of Warner Chilcott plc ... statement of Actavis and Warner Chilcott (the "Form ... Actavis and Warner Chilcott have entered into a ...
(Date:6/18/2013)... 2013  It has become apparent that a ... Mobility, a subsidiary company of The Scooter Store, ... appears to be due to the ongoing bankruptcy ... employees.  (Logo: http://photos.prnewswire.com/prnh/20130402/CG87448LOGO ) ... clients are complex mobility users with significant disabilities, ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 2Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 3Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 4Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 5Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 6Actavis Files Registration Statement on Form S-4 in Connection with Proposed Warner Chilcott Acquisition 7
(Date:6/18/2013)... commercial venture, using technology developed at Case Western ... Case School of Engineering, has made available avatarsvirtual ... graduate students and others training to evaluate speech-language ... reducing stress on the trainee, because a diagnosis ... person. , Graduate students studying to become ...
(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) ... President’s Emergency Plan for AIDS Relief (PEPFAR) to mark ... in the global effort to eliminate pediatric HIV/AIDs. ... of June 2013, one million babies globally have been ... inception in 2003, EGPAF has been a key implementer ...
(Date:6/18/2013)... A new $119 million industry is taking ... is redefining the way consumers get their seafood. ... culinary chefs on the Emerald Coast panhandle of Northwest ... and the promising industry of aquaculture. , The word ... strive to fully partake in the effort, especially when ...
(Date:6/18/2013)... New York magazine named 145 physicians from The ... up from 129 last year and more than any individual ... 52 additional doctors who serve at hospitals within Mount Sinai’s ... “Best Doctors” issue, which this year features a total of ... is available online at http://www.nymag.com/bestdoctors . , “America is ...
(Date:6/18/2013)... People with HIV are more likely to keep their ... if they feel their physician listens, explains things ... a "case," new Johns Hopkins research suggests. , "If ... to them, they feel that doctor has their best ... follow medical advice," says study leader Tabor E. Flickinger, ...
Breaking Medicine News(10 mins):Health News:SimuCase avatars advance speech-language pathology training 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3Health News:New $119 Million Industry Swimming Up the East Coast 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 2Health News:Mount Sinai Tops the List in New York Magazine’s 2013 “Best Doctors” Issue 3Health News:Respect may be the key to stopping patient 'no shows' 2
... to be held Wednesday, September 16, 2009 LOS ... Summit Entertainment, will be honored at the 35th annual ... California Chapter of the National Multiple Sclerosis Society. ... 16, 2009 at the Century Plaza Hotel in Los ...
... the annual meeting of the American Academy of Neurology ... , Like a quiz show, Neurobowl awards points for ... wrong answers. The tougher the question, the higher the ... neurological conditions, based on symptoms, video clips, X-rays, etc. ...
... April 16 JAZD Markets, the leader in on-line B2B ... platforms, today announced that David Southwick has joined the company ... Southwick will be focused on building out JAZD Markets, sales ... trade associations. "Dave brings a proven career of building ...
... SACRAMENTO, Calif., April 16 The California ... 31 deadline is rapidly approaching to have your kindergartener ... the 2009-10 school year.The requirement has been in effect ... most common chronic childhood disease, it is essential that ...
... Lamb & Apples WellBars Guaranteed to Make Dogs Even Happier ... responsible pet parents who want to show their dogs a ... Wellness WellBars flavors to choose from. The ... announces the availability of two NEW meat-based varieties ...
... Chosen to Accurately Identify Donors at Allahabad ... M2SYS Technology, an award-winning fingerprint biometrics research ... Enterprise Solutions has integrated M2SYS, Bio-Plugin(TM) fingerprint ... blood donor management system. The biometric ...
Cached Medicine News:Health News:The National Multiple Sclerosis Society's 35th Annual Dinner of Champions to Honor Summit Entertainment's Rob Friedman 2Health News:What do neurologists do for entertainment? 2Health News:JAZD.net Adds David Southwick as SVP of Sales and Service 2Health News:California Dental Association Reminds Parents of Kindergarten Dental Check-Up Requirement 2Health News:New Wellness(R) WellBars(R) Dog Snack Flavors Receive a Round of 'Paw-pplause' 2Health News:M2SYS Fingerprint Biometrics System Selected by VinDec Enterprise Solutions to Verify Blood Donors 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: